vs
MERIT MEDICAL SYSTEMS INC（MMSI）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs 9.6%，领先168.1%）。MERIT MEDICAL SYSTEMS INC同比增速更快（10.9% vs -150.5%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
MMSI vs TFX — 直观对比
营收规模更大
MMSI
是对方的-1.0倍
$-401.9M
营收增速更快
MMSI
高出161.4%
-150.5%
净利率更高
TFX
高出168.1%
9.6%
自由现金流更多
MMSI
多$167.0M
$-92.9M
两年增速更快
TFX
近两年复合增速
10.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $393.9M | $-401.9M |
| 净利润 | $38.0M | $-714.3M |
| 毛利率 | 49.6% | — |
| 营业利润率 | 13.8% | — |
| 净利率 | 9.6% | 177.8% |
| 营收同比 | 10.9% | -150.5% |
| 净利润同比 | 36.0% | -422.7% |
| 每股收益（稀释后） | $0.64 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MMSITFX
| Q4 25 | $393.9M | $-401.9M | ||
| Q3 25 | $384.2M | $913.0M | ||
| Q2 25 | $382.5M | $780.9M | ||
| Q1 25 | $355.4M | $700.7M | ||
| Q4 24 | $355.2M | $795.4M | ||
| Q3 24 | $339.8M | $764.4M | ||
| Q2 24 | $338.0M | $749.7M | ||
| Q1 24 | $323.5M | $737.8M |
净利润MMSITFX
| Q4 25 | $38.0M | $-714.3M | ||
| Q3 25 | $27.8M | $-408.9M | ||
| Q2 25 | $32.6M | $122.6M | ||
| Q1 25 | $30.1M | $95.0M | ||
| Q4 24 | $27.9M | $-136.7M | ||
| Q3 24 | $28.4M | $111.0M | ||
| Q2 24 | $35.7M | $80.0M | ||
| Q1 24 | $28.2M | $15.3M |
毛利率MMSITFX
| Q4 25 | 49.6% | — | ||
| Q3 25 | 48.5% | 49.5% | ||
| Q2 25 | 48.2% | 55.2% | ||
| Q1 25 | 48.4% | 55.6% | ||
| Q4 24 | 48.7% | 55.3% | ||
| Q3 24 | 46.4% | 56.3% | ||
| Q2 24 | 47.7% | 55.6% | ||
| Q1 24 | 46.9% | 56.4% |
营业利润率MMSITFX
| Q4 25 | 13.8% | — | ||
| Q3 25 | 11.1% | -44.8% | ||
| Q2 25 | 12.3% | 19.9% | ||
| Q1 25 | 11.5% | 17.9% | ||
| Q4 24 | 10.3% | -13.9% | ||
| Q3 24 | 11.0% | 19.5% | ||
| Q2 24 | 13.6% | 15.6% | ||
| Q1 24 | 11.1% | -0.6% |
净利率MMSITFX
| Q4 25 | 9.6% | 177.8% | ||
| Q3 25 | 7.2% | -44.8% | ||
| Q2 25 | 8.5% | 15.7% | ||
| Q1 25 | 8.5% | 13.6% | ||
| Q4 24 | 7.9% | -17.2% | ||
| Q3 24 | 8.4% | 14.5% | ||
| Q2 24 | 10.6% | 10.7% | ||
| Q1 24 | 8.7% | 2.1% |
每股收益（稀释后）MMSITFX
| Q4 25 | $0.64 | $-15.85 | ||
| Q3 25 | $0.46 | $-9.24 | ||
| Q2 25 | $0.54 | $2.77 | ||
| Q1 25 | $0.49 | $2.07 | ||
| Q4 24 | $0.46 | $-2.89 | ||
| Q3 24 | $0.48 | $2.36 | ||
| Q2 24 | $0.61 | $1.69 | ||
| Q1 24 | $0.48 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $446.4M | $378.6M |
| 总债务越低越好 | $734.0M | $2.6B |
| 股东权益账面价值 | $1.6B | $3.1B |
| 总资产 | $2.7B | $6.9B |
| 负债/权益比越低杠杆越低 | 0.46× | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资MMSITFX
| Q4 25 | $446.4M | $378.6M | ||
| Q3 25 | $392.5M | $354.0M | ||
| Q2 25 | $341.8M | $253.7M | ||
| Q1 25 | $395.5M | $284.1M | ||
| Q4 24 | $376.7M | $290.2M | ||
| Q3 24 | $523.1M | $243.2M | ||
| Q2 24 | $636.7M | $238.6M | ||
| Q1 24 | $581.9M | $237.4M |
总债务MMSITFX
| Q4 25 | $734.0M | $2.6B | ||
| Q3 25 | $732.9M | $2.7B | ||
| Q2 25 | $731.8M | $1.9B | ||
| Q1 25 | $730.7M | $1.9B | ||
| Q4 24 | $729.6M | $1.7B | ||
| Q3 24 | $750.5M | — | ||
| Q2 24 | $801.3M | — | ||
| Q1 24 | $800.1M | — |
股东权益MMSITFX
| Q4 25 | $1.6B | $3.1B | ||
| Q3 25 | $1.5B | $3.8B | ||
| Q2 25 | $1.5B | $4.2B | ||
| Q1 25 | $1.4B | $4.1B | ||
| Q4 24 | $1.4B | $4.3B | ||
| Q3 24 | $1.3B | $4.5B | ||
| Q2 24 | $1.3B | $4.6B | ||
| Q1 24 | $1.2B | $4.5B |
总资产MMSITFX
| Q4 25 | $2.7B | $6.9B | ||
| Q3 25 | $2.6B | $7.9B | ||
| Q2 25 | $2.6B | $7.4B | ||
| Q1 25 | $2.5B | $7.2B | ||
| Q4 24 | $2.4B | $7.1B | ||
| Q3 24 | $2.4B | $7.5B | ||
| Q2 24 | $2.4B | $7.4B | ||
| Q1 24 | $2.3B | $7.5B |
负债/权益比MMSITFX
| Q4 25 | 0.46× | 0.85× | ||
| Q3 25 | 0.48× | 0.70× | ||
| Q2 25 | 0.49× | 0.45× | ||
| Q1 25 | 0.51× | 0.47× | ||
| Q4 24 | 0.53× | 0.39× | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.62× | — | ||
| Q1 24 | 0.65× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $98.5M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $74.0M | $-92.9M |
| 自由现金流率自由现金流/营收 | 18.8% | 23.1% |
| 资本支出强度资本支出/营收 | 6.2% | -0.2% |
| 现金转化率经营现金流/净利润 | 2.59× | — |
| 过去12个月自由现金流最近4个季度 | $215.7M | $1.4M |
8季度趋势，按日历期对齐
经营现金流MMSITFX
| Q4 25 | $98.5M | $-92.3M | ||
| Q3 25 | $75.0M | $107.8M | ||
| Q2 25 | $83.3M | $7.8M | ||
| Q1 25 | $40.6M | $73.3M | ||
| Q4 24 | $68.7M | $202.6M | ||
| Q3 24 | $47.3M | $231.1M | ||
| Q2 24 | $68.5M | $91.7M | ||
| Q1 24 | $36.2M | $112.8M |
自由现金流MMSITFX
| Q4 25 | $74.0M | $-92.9M | ||
| Q3 25 | $52.5M | $77.8M | ||
| Q2 25 | $69.6M | $-26.8M | ||
| Q1 25 | $19.5M | $43.3M | ||
| Q4 24 | $65.3M | $170.6M | ||
| Q3 24 | $38.0M | $209.9M | ||
| Q2 24 | $57.9M | $56.9M | ||
| Q1 24 | $24.5M | $74.4M |
自由现金流率MMSITFX
| Q4 25 | 18.8% | 23.1% | ||
| Q3 25 | 13.7% | 8.5% | ||
| Q2 25 | 18.2% | -3.4% | ||
| Q1 25 | 5.5% | 6.2% | ||
| Q4 24 | 18.4% | 21.4% | ||
| Q3 24 | 11.2% | 27.5% | ||
| Q2 24 | 17.1% | 7.6% | ||
| Q1 24 | 7.6% | 10.1% |
资本支出强度MMSITFX
| Q4 25 | 6.2% | -0.2% | ||
| Q3 25 | 5.8% | 3.3% | ||
| Q2 25 | 3.6% | 4.4% | ||
| Q1 25 | 5.9% | 4.3% | ||
| Q4 24 | 1.0% | 4.0% | ||
| Q3 24 | 2.8% | 2.8% | ||
| Q2 24 | 3.1% | 4.6% | ||
| Q1 24 | 3.6% | 5.2% |
现金转化率MMSITFX
| Q4 25 | 2.59× | — | ||
| Q3 25 | 2.70× | — | ||
| Q2 25 | 2.56× | 0.06× | ||
| Q1 25 | 1.35× | 0.77× | ||
| Q4 24 | 2.46× | — | ||
| Q3 24 | 1.66× | 2.08× | ||
| Q2 24 | 1.92× | 1.15× | ||
| Q1 24 | 1.28× | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
TFX
暂无分部数据
